Evidence supporting the use of: Tetrahydrocannabinol
For the health condition: Multiple Sclerosis

Links: Go back one page, Tool main page, Ingredients list, Health conditions list, Body systems list

Synopsis

Source of validity: Scientific
Rating (out of 5): 3

Tetrahydrocannabinol (THC), the primary psychoactive component of cannabis, has been investigated for its potential to alleviate symptoms of Multiple Sclerosis (MS), particularly spasticity and pain. Several randomized controlled trials and systematic reviews, including those cited by the American Academy of Neurology (AAN) and Cochrane Reviews, indicate that oral cannabis extracts containing THC, as well as synthetic THC analogs like dronabinol and nabiximols, may provide modest benefits for spasticity symptoms reported by patients. However, the objective clinical improvement in muscle tone and mobility is often less pronounced than patient-reported outcomes. The AAN’s 2014 guideline concluded that oral cannabis extract and synthetic THC are “probably effective” for reducing patient-reported spasticity and pain in MS, but evidence is insufficient for other MS-related symptoms such as tremor or bladder dysfunction. Several studies note the potential for adverse effects including cognitive impairment, dizziness, and fatigue. Due to the psychoactive nature of THC and variability in individual response, THC-containing products are typically considered after standard antispasticity medications have failed or are not tolerated. Thus, while there is scientific validation supporting the use of THC for specific symptoms of MS, particularly for patient-reported spasticity and pain, the overall quality of evidence is moderate, and long-term safety remains a concern. THC is not a cure for MS, but may offer symptomatic relief for some patients under clinical supervision.

More about Tetrahydrocannabinol
More about Multiple Sclerosis

Products containing Tetrahydrocannabinol

We currently have no products on Vitabase that contain this ingredient.